[go: up one dir, main page]

MX2022003032A - Oxinitruro de piridina, metodo para su preparacion y uso de este. - Google Patents

Oxinitruro de piridina, metodo para su preparacion y uso de este.

Info

Publication number
MX2022003032A
MX2022003032A MX2022003032A MX2022003032A MX2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A
Authority
MX
Mexico
Prior art keywords
preparation
pyridine
sodium ion
ion channel
method therefor
Prior art date
Application number
MX2022003032A
Other languages
English (en)
Inventor
Yan Ye
Jianbiao Peng
Haibing Guo
Qiong Zhang
Zhongli Wang
Ming Dai
Fengkai Cheng
Jiu Luo
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of MX2022003032A publication Critical patent/MX2022003032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención pertenece al campo de la química médica. Se divulgan un oxinitruro de piridina, un método para su preparación y el uso de este. Específicamente, la presente invención se refiere a una serie de bloqueantes de los canales iónicos de sodio con una nueva estructura, un método para su preparación y el uso de estos. La estructura de estos es como se muestra en a continuación en la fórmula general (I). Los compuestos o un estereoisómero, un racemato, un isómero geométrico, un tautómero, un profármaco, un hidrato, un solvato o una sal farmacéuticamente aceptable de estos y una composición farmacéutica se puede utilizar para tratar o/y prevenir enfermedades relacionadas mediadas por un canal iónico de sodio (NaV). (ver Fórmula).
MX2022003032A 2019-09-12 2020-09-11 Oxinitruro de piridina, metodo para su preparacion y uso de este. MX2022003032A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910863718 2019-09-12
CN201911094782 2019-11-11
CN202010531381 2020-06-11
CN202010923311 2020-09-04
PCT/CN2020/114700 WO2021047622A1 (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
MX2022003032A true MX2022003032A (es) 2022-07-12

Family

ID=74866555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003032A MX2022003032A (es) 2019-09-12 2020-09-11 Oxinitruro de piridina, metodo para su preparacion y uso de este.

Country Status (17)

Country Link
US (1) US20230303495A9 (es)
EP (1) EP4043437A4 (es)
JP (1) JP2022548104A (es)
KR (1) KR20220101606A (es)
CN (3) CN112479996B (es)
AU (1) AU2020346951A1 (es)
BR (1) BR112022004495A8 (es)
CA (1) CA3150400A1 (es)
CL (1) CL2022000619A1 (es)
CO (1) CO2022004594A2 (es)
GE (2) GEAP202415928A (es)
MX (1) MX2022003032A (es)
PE (1) PE20221515A1 (es)
PH (1) PH12022550584A1 (es)
TW (1) TWI770607B (es)
WO (1) WO2021047622A1 (es)
ZA (1) ZA202204100B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018348A2 (pt) * 2021-03-11 2023-12-05 Jiangxi Jemincare Group Co Ltd Forma de cristal de composto de óxido de nitrogênio e piridina e uso da mesma
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
IL308954A (en) 2021-06-04 2024-01-01 Vertex Pharma Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023186102A1 (zh) * 2022-04-02 2023-10-05 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
EP4511116A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
US20250388543A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN119212980A (zh) 2022-06-02 2024-12-27 上海济煜医药科技有限公司 吡啶氮氧化合物的制备方法
AU2023287273A1 (en) * 2022-06-22 2025-01-09 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Nav1.8 inhibitor
JP2026501116A (ja) 2022-12-06 2026-01-14 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のための製造方法
WO2024153856A1 (en) * 2023-01-18 2024-07-25 Orion Corporation Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide
WO2024255833A1 (zh) * 2023-06-14 2024-12-19 上海济煜医药科技有限公司 吡啶氮氧化合物与富马酸的共晶体及其组合物、用途和制备方法
WO2024255834A1 (zh) * 2023-06-14 2024-12-19 上海济煜医药科技有限公司 吡啶氮氧化合物的盐型、共晶及其制备方法和应用
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TW202540069A (zh) * 2023-12-13 2025-10-16 大陸商武漢人福創新藥物研發中心有限公司 Nav1.8抑制劑化合物及其鹽、多晶型和用途
WO2026006674A1 (en) 2024-06-28 2026-01-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635254T2 (de) * 1995-07-07 2006-07-13 Astrazeneca Ab Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
JP5149003B2 (ja) * 2005-06-21 2013-02-20 三井化学アグロ株式会社 アミド誘導体ならびに該化合物を含有する殺虫剤
US8841483B2 (en) * 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP2010047480A (ja) * 2006-12-19 2010-03-04 Mitsui Chemicals Inc 虫害の予防方法
EP2212292B1 (en) * 2007-10-11 2012-12-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
MX2010003865A (es) * 2007-10-11 2010-06-01 Vertex Pharma Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
US9656959B2 (en) * 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
TWI659945B (zh) * 2013-01-31 2019-05-21 維泰克斯製藥公司 作爲鈉通道調節劑之醯胺
KR102226587B1 (ko) * 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
NZ710270A (en) * 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
DK3080134T3 (en) * 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS
BR112020000553A2 (pt) * 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio
CA3105657A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8

Also Published As

Publication number Publication date
BR112022004495A2 (pt) 2022-05-31
BR112022004495A8 (pt) 2023-04-18
PH12022550584A1 (en) 2024-03-04
GEAP202415928A (en) 2024-07-10
CA3150400A1 (en) 2021-03-18
EP4043437A1 (en) 2022-08-17
ZA202204100B (en) 2024-04-24
GEP20247688B (en) 2024-11-11
CN118146148A (zh) 2024-06-07
CN113906013A (zh) 2022-01-07
US20230303495A9 (en) 2023-09-28
JP2022548104A (ja) 2022-11-16
KR20220101606A (ko) 2022-07-19
EP4043437A4 (en) 2023-10-04
PE20221515A1 (es) 2022-10-04
CN113906013B (zh) 2024-03-12
TW202114990A (zh) 2021-04-16
CO2022004594A2 (es) 2022-07-08
TWI770607B (zh) 2022-07-11
AU2020346951A1 (en) 2022-04-28
WO2021047622A1 (zh) 2021-03-18
CL2022000619A1 (es) 2022-10-28
CN112479996A (zh) 2021-03-12
US20230026907A1 (en) 2023-01-26
CN112479996B (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
MX2022003032A (es) Oxinitruro de piridina, metodo para su preparacion y uso de este.
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
PH12021550958A1 (en) Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
EA201792116A1 (ru) Ингибитор янус-киназы
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators